Legacy Capital Wealth Partners LLC Acquires New Holdings in Sanofi (NASDAQ:SNY)

Legacy Capital Wealth Partners LLC bought a new position in shares of Sanofi (NASDAQ:SNY) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 11,332 shares of the company’s stock, valued at approximately $550,000.

A number of other institutional investors have also recently bought and sold shares of SNY. Bank of New York Mellon Corp raised its position in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the last quarter. Mondrian Investment Partners LTD raised its holdings in shares of Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Sanofi in the fourth quarter worth $51,520,000. BNP Paribas Financial Markets boosted its holdings in Sanofi by 3,440.6% during the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock worth $50,230,000 after purchasing an additional 1,004,358 shares during the last quarter. Finally, Morningstar Investment Services LLC grew its position in Sanofi by 99.5% in the fourth quarter. Morningstar Investment Services LLC now owns 1,486,949 shares of the company’s stock valued at $73,425,000 after purchasing an additional 741,456 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of SNY opened at $57.53 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a 50-day moving average of $52.23 and a 200-day moving average of $49.60. The company has a market cap of $145.71 billion, a PE ratio of 28.91, a price-to-earnings-growth ratio of 1.60 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $57.92.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter in the previous year, the business earned $0.95 earnings per share. The business’s revenue was up 7.8% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 4.23 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.